Slide 1: We Make Life Better
We Make Life Better ) BioLargo May 18, 2023, OTCQB: BLGO. Westminster, CA Safe Harbor Sctarart ‘he seman cad eran, wich oe ro ste, reformat sateen tha ae se sand wera hat aud nea ess flr maeely fm Me eres fatale seer, cut, bt nt wma, he ‘sand unmanned ego scent and fue fags wth te Seates and Exhange
Slide 2: BioLargo family: Environmental Group and Medical subsidiary
by BioLargo We Make Life Better Gy Biolargo OBioLargo Water © Engnosing, Seerce Toco} “je * CONVIENVIRONMENTAL C ly R A we Medical Technologies Ine v Vv Environmental Group Medical subsidiary — plan is to spin-out when ready GBiolergo 2
Slide 3: PFAS Commercial Update
Slide 4: POOPH - Consumer pet odor product
POOPH - Consumer pet odor product Product marketed and sold by our partners, award-winning consumer product experts (Ikigai Marketing Works) ONM receives manufacturer's margin and a royalty on sales Business strategy: ramp up sales and sell to a major consumer products company + ONM would receive 20
Slide 5: BioLargo Sodium-Sulfur Battery
BioLargo Sodium-Sulfur Battery > Competitive energy density Compa to Lithium > Targeting fixed site energy storage > Safer, more thermally stable > More cost-effective > Unlimited charge/discharge cycles > 100% domestic supply possible > Far superior environmental outcomes > Better option for long d
Slide 6: CLYRA Medical Technologies
CLYRA Medical Technologies Inc v v v Orthopedic Wound and Burn Dental and Oral Surgery BioLargo owns 58% jirector hired gning up Clyra™ Antimicrobial Platform Infection Prevention & Control
Slide 7: Quarterly Revenue (2021 to Q1 2023)
QUARTERLY REVENUE (2021 TO Q1 2023) eH Revenue $4.0 8 8-quarter average: 29.4% increase MILLIONS s ro 4 132% annual increase vs. 2021 x Q3 a4 Qi Q2 Q3 a4 Qi 2021 2022 2023 2. $0.0 fo Qi Q Trends are not necessarily indicative of future performance
Slide 8: Revenue vs Debt
$4.0 $2.5 MILLIONS s ro $15 Qi Q2 Q3 2021 REVENUE VS DEBT Pe Revenue H-Debt a4 Qi Q2 Q3 a4 Qi 2022 2023 Trends are not necessarily indicative of future performance
Slide 9: Revenue vs Net Loss
MILLIONS & $0 -$10 -$2.0 -$3.0 REVENUE VS NET LOSS me Revenue ~BNet Loss Trends are not necessarily indicative of future performance
Slide 10: Revenue vs SG&A
$4.0 $2.5 MILLIONS s ro $15 Qi Q2 Q3 2021 REVENUE VS SG&A eRevene HSGRA a4 Qi Q2 Q3 a4 Qi 2022 2023 Trends are not necessarily indicative of future performance
Slide 11: Revenue vs Net Cash Generated/Used in Operating Activities
$4.0 6 ” 8 ret) oS ry MILLIONS 6 $0 $1.0 $2.0 REVENUE VS NET CASH GENERATED/USED IN OPERATING ACTIVITIES —tRevenue “®=Net cash used/generated in operating activities Qi 2023 Trends are not necessarily indicative of future performance
Slide 12: Net Stockholders' Equity (5.25 Years)
$4.0 $30 $20 $10 MILLIONS “$10 $3.0 2018 NET STOCKHOLDER'S EQUITY (5.25 YEARS) Increase of >$5.5 million 2023 (Q1 ONLY) Trends are not necessarily indicative of future performance
Slide 13: Additional Financial Information
Additional Financial Information Consolidated Revenues $3,742,000 revenue Q1 * Q1 2023 revenues 78% greater than Q4 2022 * Net loss reduced to $494,000, down from $1,544,000 in Q1 2022 (68% decrease) * Substantially improved cash position: $3,264,000, compared to $974,000 in Q1 2022 Subsidiaries ONM
Slide 14: The BioLargo Family of Companies
The BioLargo 6 BioLargo Family of Companies We Make life Better BioLargo, Inc. is a sustainable science, technology & full-service enviromental - ngineering compan) i f ivering world awe engineering company that makes ifebetter _by delivering world-class Mave products and services across a broad ran